Worth reading
61In focus
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
8.7
Year-on-year revenue growth (%)Wording
Conditional
How definitive the wording is.Results for this period
Third quarter2023年6月1日〜2024年2月29日ConsolidatedJapanese GAAPNet Sales45,373¥ millionYear on year +8.7%Progress 72.3%
Operating profit830¥ millionYear on year -7.3%Progress 94.0%
Ordinary income871¥ millionYear on year -7.0%Progress 93.2%
Net income attributable to owners of the parent442¥ millionProgress 133.5%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share173.23円
Financial position at period-end
Total assets25,633¥ million
of which net assets 8,409 ¥ millionEquity ratio 32.8%vs. prior year-end +0.6pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenue
Medical device sales45,36599.4%+9.0%
Medical Equipment Manufacturing and Sales2090.5%-1.0%
Medical Mall Business510.1%+1.7%
Segment profit
Medical device sales1,67199.8%+6.1%
Medical Equipment Manufacturing and Sales20.1%-79.7%
Medical Mall Business10.1%+81.4%
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥62,764 million (YoY +7.9%)
Operating profit¥883 million (YoY -23.6%)
Ordinary income¥935 million (YoY -22.5%)
Net income¥331 million (YoY +51.5%)
Annual Dividend Forecast¥48.00 → ¥55.00
Factors Behind Changes in Business Performance
設備投資需要の増加、検査・手術件数の回復による医療機器消耗品の売上回復・増加、販売費及び一般管理費の増加、物流センター開設予定に伴う減損損失の計上。
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 1 / Company name 株式会社鹿児島オルソ・メディカル / Excluded Number of companies 0 / Company name Not disclosed / 表紙の重要な子会社の異動 No
Impairment loss¥200 million
Breakdown of extraordinary income (loss)Extraordinary income Reversal of allowance for doubtful accounts ¥54 million / Extraordinary loss Loss on sale of fixed assets ¥4 million, Impairment Losses ¥200 million
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNone (対象者：Not disclosed)
Issued Shares at Period-End2,553,000 shares
Treasury Shares at Period-End114株
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2023年6月1日〜2024年2月29日 |
| Net Sales | ¥45,373 million (YoY +8.7%) |
| Operating profit | ¥830 million (YoY -7.3%) |
| Ordinary income | ¥871 million (YoY -7.0%) |
| Profit attributable to owners of the parent | ¥442 million |
| Net income per share | 173.23円 |
| Equity ratio | End of the current fiscal period 32.8 / End of previous period 32.2 |
| Total assets | ¥25,633 million |
| Net assets | ¥8,409 million |
| Full-year earnings forecast | Net Sales ¥62,764 million (YoY +7.9%) / Operating profit ¥883 million (YoY -23.6%) / Ordinary income ¥935 million (YoY -22.5%) / Net income ¥331 million (YoY +51.5%) |
| Annual Dividend Forecast | ¥48.00 → ¥55.00 |
| Segment revenue | Medical device sales ¥45,365 million (YoY +9.0%) / Medical Equipment Manufacturing and Sales ¥209 million (YoY -1.0%) / Medical Mall Business ¥51 million (YoY +1.7%) |
| Segment profit | Medical device sales ¥1,671 million (YoY +6.1%) / Medical Equipment Manufacturing and Sales ¥2 million (YoY -79.7%) / Medical Mall Business ¥1 million (YoY +81.4%) |
| Impairment loss | ¥200 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Reversal of allowance for doubtful accounts ¥54 million / Extraordinary loss Loss on sale of fixed assets ¥4 million, Impairment Losses ¥200 million |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 1 / Company name 株式会社鹿児島オルソ・メディカル / Excluded Number of companies 0 / Company name Not disclosed / 表紙の重要な子会社の異動 No |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | None (対象者：Not disclosed) |
| Issued Shares at Period-End | 2,553,000 shares |
| Treasury Shares at Period-End | 114株 |
| Factors Behind Changes in Business Performance | 設備投資需要の増加、検査・手術件数の回復による医療機器消耗品の売上回復・増加、販売費及び一般管理費の増加、物流センター開設予定に伴う減損損失の計上。 |
Items this document does not state (12)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogDepreciation and amortizationMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.売上高は、設備投資需要の増加と、検査・手術件数の回復による診療材料等の医療機器消耗品の売上回復・増加により伸長した。営業利益・経常利益は販売費及び一般管理費の増加により減少し、親会社株主に帰属する四半期純利益は、物流センター開設予定に伴う減損損失2億円を計上した前年同期と比べて増加した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.